A Phase 1B Study of AMG-232 in Combination With Decitabine in Acute Myeloid Leukemia
Phase of Trial: Phase I
Latest Information Update: 21 Feb 2018
At a glance
- Drugs AMG 232 (Primary) ; Decitabine (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 07 Feb 2018 Status changed from recruiting to suspended, as protocol amendment is required.
- 04 Jan 2018 Planned number of patients changed from 40 to 58.
- 20 Oct 2017 Planned End Date changed from 31 Mar 2019 to 31 Oct 2019.